health news today obesity drugs glp-1 Use of to Treat Overweight or Increased 587 Percent from 2019 to 2024, According to New FAIR Study Seniors abandon GLP-1 weight-loss drugs
Description
Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA
Discontinuation rates undermined the value argument Cost alone might not have tipped the scales
[DOI] [PubMed] [Google Scholar] 81.Dore DD, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD
This agreement is an important step toward making effective treatment more accessible to the people who need it, including many here in our local community, said Dr
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
24, Dec
